BiTE Therapy Toxicities: Cytokine Release Syndrome (CRS)-BiTE Therapy Toxicities Infographic

Pdf Summary

This document is a quick clinical guide for nurses and care teams managing <strong>cytokine release syndrome (CRS/SLC)</strong> associated with <strong>BiTE immunotherapies</strong> in <strong>small cell lung cancer</strong>.

Key points:
- <strong>What causes CRS:</strong> BiTEs redirect T cells to attack tumor cells, which can trigger <strong>rapid cytokine release</strong> from immune overactivation.
- <strong>Symptoms to watch for:</strong> <strong>Fever, hypotension, rigors, malaise, tachycardia, hypoxia, and organ dysfunction</strong>.
- <strong>Risk pattern over time:</strong> CRS is most common at treatment start, with about <strong>40% incidence on Cycle 1 Day 1</strong> for grade 1–2 events. It drops to around <strong>30% by Day 8</strong>, <strong>8–10% by Day 15</strong>, and decreases sharply in later cycles.
- <strong>Monitoring and workflow:</strong>  
  - Review <strong>autoimmune history</strong> before infusion.  
  - Perform a <strong>baseline neurological assessment</strong>.  
  - Educate the patient and caregiver about CRS and dose escalation.  
  - Monitor <strong>vital signs continuously</strong>, especially during the first <strong>0–8 hours</strong> after infusion.  
  - Document and track fever, and provide post-infusion instructions on hydration and symptom reporting.
- <strong>Management by severity:</strong>  
  - Supportive care includes <strong>fluids, oxygen, and antipyretics</strong>.  
  - <strong>Tocilizumab</strong> (or siltuximab/biosimilar) is used for <strong>IL-6 blockade</strong>.  
  - <strong>Steroids</strong> such as dexamethasone may be used.  
  - <strong>Hold BiTE therapy</strong> until CRS resolves; <strong>ICU care</strong> is recommended for hemodynamically unstable patients.  
  - <strong>Vasopressors</strong> may be needed in severe cases.  
  - For <strong>tarlatamab</strong>, recurrent <strong>grade 3 CRS</strong> may require discontinuation.

Overall, the document emphasizes <strong>early recognition, close monitoring, patient education, and prompt intervention</strong> to safely manage CRS during BiTE treatment.

Asset Subtitle

Translated with Canva and ChatGPT. Verified by committee member.

Keywords

cytokine release syndrome

CRS

BiTE immunotherapies

small cell lung cancer

T-cell activation

tocilizumab

hypotension

fever

patient monitoring

immune overactivation